ALKS - Alkermes plc
(NaN%)
Sell
Moderate Growth and Improving●Stock Price Very High
57%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -12.31%
Operating Income Growth is -16.5%
Net Income Growth is -18.81%
Earnings Per Share (EPS) Growth is -37.01%
Net Margin is 23.3%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.33
Debt Ratio is 0.27
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is STRONG
Cash from Operations Growth is 16.46%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alkermes plc (ALKS) - alkermes.com
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Richard F. Pops
Employees - 2,482
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.